Mounjaro aims for 'diabetes·obesity' synergy
By Whang, byung-woo | translator Hong, Ji Yeon
24.11.19 05:05:01
가나다라
0
Mounjaro expected to focus on diabetes as part of the company's strategy to secure brand awareness
73.7% of Korean patients with type 2 diabetes are overweight·obese…"high potential as a treatment"
Lily Korea proceeds to obtain reimbursement for Mounjaro…confident to stabilize the distribution network
Eli Lily's Mounjaro (tirzepatide), the first once-weekly GIP·GLP-1 receptor agonist, will enter the market with its diabetes and obesity indications.
Unlike already launched Wegovy (semaglutide), Mounjaro has two indications: diabetes and obesity.
Experts anticipate that Mounjaro's sales strategy will be focused on diabetes treatment although a separate indication is not a chief factor for medication choice in clinical practices.
▲Product photo of Mounjaro.
Mounjaro is a single molecule that activates both GIP and GLP-1 receptors, which are primary incretin hormones that stimulate insulin secretion in the body.
Mounjaro received the Ministry of Food and Drug Safety (MFDS) approval
Whang, byung-woo(tuai@dailypharm.com)
If you want to see the full article, please JOIN US (click)